

Clinical Validation of a Polymerase Chain Reaction Assay for the Diagnosis of Pertussis by Comparison With Serology, Culture, and Symptoms During a Large Pertussis Vaccine Efficacy Trial

Ulrich Heininger, MD*; Gabriela Schmidt-Schlöpfer, PhD‡; James D. Cherry, MD, MSc§; and Klemens Stehr, MD*

ABSTRACT. *Objective.* To assess the diagnostic sensitivity and specificity of a *Bordetella pertussis* polymerase chain reaction (PCR) assay using nasopharyngeal (NP) specimens from subjects with cough illnesses participating in a large pertussis vaccine efficacy trial.

Design. From 1991 to 1994, we conducted a large pertussis vaccine efficacy trial in Germany to determine the efficacy of the Lederle/Takeda acellular pertussis component diphtheria-tetanus toxoids in comparison with the Lederle whole-cell component diphtheria-tetanus toxoids vaccine. In the final year of the follow-up period of this trial, a second NP specimen for PCR, in addition to a culture specimen and blood for specific serology (enzyme-linked immunosorbent assay), was collected by use of a Dacron swab in subjects or family members with cough illnesses ≥ 7 days duration or in subjects with exposure to a cough illness in a household member to establish a diagnosis of *B pertussis* infection. Oligonucleotide primers (pTp1 and pTp2) that amplify a 191-bp-sized DNA fragment from the pertussis toxin operon, which is specific for *B pertussis*, were used. The PCR-amplified products were visualized by dot blot analysis followed by hybridization with a digoxigenin labeled probe and rated as 1+, 2+, or 3+ in comparison with positive controls representing ~ 1 to 10, 11 to 50, and > 50 *B pertussis* organisms, respectively. In the present analysis, we compare PCR findings with those of serology, culture, positive household contact, and clinical characteristics of cough illnesses.

Results. Of 392 subjects with NP specimens obtained for PCR, 376 also had NP specimens collected for culture and 282 had serum specimens. PCR and culture were positive in 86 (22%) and 23 (6%) subjects, respectively. Of the positive PCR specimens, 40 were rated 3+, 32 were rated 2+, and 14 were rated 1+; 3+ positive specimens were more prevalent among DT recipients compared with pertussis vaccine recipients. Illnesses in subjects with 3+ positive PCR results were more typical of pertussis than were those in subjects with 2+ and 1+ positive results with a mean duration of cough of 48 days versus 43 and 42 days, respectively; presence of parox-

ysms, whoop or vomiting in 38% versus 17% and 10%, respectively; and a clinical diagnosis of definite or probable pertussis by the investigators of 26% versus 7% and 4%, respectively. Using serologic evidence of infection as the standard, sensitivity of PCR was 61%, and specificity was 88%. For 3+ positive PCR results, the respective values were 42% and 97%.

Conclusion. Our findings demonstrate that PCR is more sensitive than conventional culture for the diagnosis of pertussis. They also demonstrate a high specificity of PCR when serology with or without other confirmatory criteria (culture and household contact) is used as the reference. Analysis of semiquantitative PCR results revealed that subjects with a 3+ PCR more frequently experienced typical illness compared with patients with 1+ or 2+ PCR. Although specific serologic study remains a necessity in pertussis research its modification for diagnosis in the clinical setting results in low sensitivity and specificity. Therefore, because PCR is more sensitive than culture and is easy to perform, it is a useful addition in the clinical setting. *Pediatrics* 2000;105(3). URL: <http://www.pediatrics.org/cgi/content/full/105/3/e31>; *Bordetella pertussis, pertussis vaccine, polymerase chain reaction, serology, culture, clinical validation.*

ABBREVIATIONS. PCR, polymerase chain reaction; DTaP, diphtheria-tetanus toxoids, acellular pertussis vaccine, adsorbed; DTP, diphtheria-tetanus toxoids, whole-cell pertussis vaccine, adsorbed; DT, diphtheria-tetanus vaccine; IgG, immunoglobulin G; IgA, immunoglobulin A; PT, pertussis toxin; FHA, filamentous hemagglutinin; MAL, minimal acute level; ELISA, enzyme-linked immunosorbent assay; NP, nasopharyngeal.

During the last 15 years, extensive worldwide efforts to develop new, less reactogenic pertussis vaccines have led to considerable new knowledge relating to clinical pertussis and its diagnosis.¹⁻¹¹ Clinical investigations in conjunction with vaccine efficacy trials led to the realization that a significant percentage of *Bordetella pertussis* infections result in relatively mild illnesses of short duration.^{1-8,10,11} A number of polymerase chain reaction (PCR) assays with primers derived from 4 different chromosomal regions have been developed for the diagnosis of *B pertussis* and *B parapertussis* infections and have been evaluated in multiple studies by comparison with culture and clinically typical pertussis.¹²⁻²⁸ In the investigational setting, however, standardized serologic assays have proven to be the most sensitive technique for the diagnosis of *Bordetella* spp infections (reviewed in reference 29).

From *Hospital for Children and Adolescents of the Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; ‡University Children's Hospital, Basel, Switzerland; and §Department of Pediatrics and the UCLA Center for Vaccine Research, University of California Los Angeles School of Medicine, Los Angeles, California.

Dr Heininger is currently with the University Children's Hospital, CH-4005 Basel, Switzerland.

Received for publication Aug 4, 1999; accepted Oct 25, 1999.

Reprint requests to (U.H.) Division of Pediatric Infectious Diseases, University Children's Hospital Basel, CH-4005, Basel, Switzerland. E-mail: heininger@ubaclu.unibas.ch

PEDIATRICS (ISSN 0031 4005). Copyright © 2000 by the American Academy of Pediatrics.

Only 4 studies have prospectively examined the sensitivity of semiquantitative PCR compared with serologic assays in subjects with cough illnesses of varied severity.^{21,25,26,28} In this article, in which we have used data from a large vaccine efficacy trial, we present PCR sensitivity and specificity data using serologic assay and other confirmative diagnostic criteria (a combination of serology, culture, and household contact) as the standard.

METHODS

The methods of the study including design, monitoring of cough illnesses, and laboratory assays have been previously presented.⁶⁻⁹ Briefly, this was a longitudinal cohort study in 227 private practices in which the Lederle/Takeda diphtheria-tetanus acellular pertussis component (DTaP) and the Lederle diphtheria-tetanus whole-cell pertussis component (DTP) vaccines were administered in a double-blind, randomized manner. The diphtheria-tetanus vaccine (DT) group was open based on parent preference. DTaP and DTP recipients received 4 doses of vaccine at 3, 4.5, 6, and 15 months of age, whereas DT recipients received 3 doses at 3, 4.5, and 15 months of age.

Sera were collected from all DTaP and DTP vaccinees 1 month after the third and fourth doses and from DT recipients at 7 months of age and 1 month after the third dose. In addition, sera were collected from a randomly selected sample of 100 subjects in each group at ~3-month intervals. These sera were used to construct antibody kinetic curves for each vaccination group so that serologic diagnosis of infection could be made by a single serum at the time of an illness in a study subject. Specifically, post third and post fourth dose kinetic curves were developed for DTaP, DTP, and DT vaccine groups. A total of 1058 sera from randomly preselected DTaP and DTP recipients were available. They were separated into the following time intervals after immunization: 14 to 63 days, 64 to 138 days, 139 to 236 days, and >236 days after the third but before the fourth dose, and 14 to 74 days, 75 to 149 days, and >149 days after the fourth dose. There was a mean of 66 (range: 34–87) serum samples per time interval per vaccine group. For each time interval, immunoglobulin G (IgG) and immunoglobulin A (IgA) antibody values against pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin, and fimbriae-2 were plotted and percentiles were determined. For each cough episode, a child's post third dose value percentile (if onset of cough was before the fourth dose) or post fourth dose value percentile (if onset of cough was after the fourth dose) was determined from the kinetic curve. The antibody value of the determined percentile, in the time interval when the cough started, was the calculated acute value. If an appropriate post third or post fourth dose serum was not available then the acute-phase value was estimated from the 95th percentile value for the respective time interval. Sera were also randomly preselected from 620 DT subjects throughout the study period for kinetic curve construction. Most of these values were below the minimal acute level (MAL), so percentiles could not be assigned. Therefore, in DT subjects the MAL was used in all periods as the calculated acute value. The MALs (IgG and IgA) for each antigen were determined by the visual examination of the frequency distribution of values in randomly preselected sera from DT vaccinees collected 2, 3, and 5 months after the second dose (~6, 7, and 9 months old). These MAL values were similar to the 95th percentile except for FHA IgG and PT IgG. For these 2 antibodies, the visual breakpoint determined a higher value. The MALs were as follows: IgG-PT, 5.7 EU/mL; FHA, 7.0 EU/mL; pertactin, 8.0 EU/mL; and fimbriae-2, 1.5 EU/mL; and IgA-PT, 3.7 EU/mL; FHA, 2.7 EU/mL; pertactin, 5.0 EU/mL; and fimbriae-2, 12.5 EU/mL.

To determine significant enzyme-linked immunosorbent assay (ELISA) antibody rises, the 95th, 99th, and 99.9th percentile fold change limits were determined from assay quantitation data supplied by Wyeth-Lederle Vaccines and Pediatrics (Pearl River, NY). The percentile fold change limits varied among the different case definitions. In subjects with only a convalescent-phase serum sample or in those in whom collection of the acute-phase specimen was late, significant rises were determined by the use of the respective postimmunization value and the calculation of the

acute-phase value from the antibody kinetic curve as described above.

For serologic diagnosis of a *Bordetella* infection, a significant antibody response to PT was considered to be caused by *B. pertussis* infection, whereas a significant antibody response to any other antigen (FHA, pertactin, or fimbriae-2) in the absence of a response to PT was considered to be caused by *B. parapertussis* infection. Specifically, for diagnosis of *B. pertussis* infection, a significant antibody rise to PT (IgG or IgA) using the 99th percentile fold limit or 2 significant rises to PT (both IgG and IgA) using the 95th percentile fold limit were required. A single positive antibody rise to PT based on the 95th percentile fold change limit was accepted if at least 1 supporting rise to FHA, pertactin, or fimbriae-2 was noted employing the 99th percentile fold change limit. For diagnosis of *B. parapertussis* infections, the 99.9th percentile fold limit was required for a single significant rise to any antigen except PT, whereas the 99th and 95th percentile fold limits were used for significant rises against 2 and ≥ 3 antigens, respectively.

For culture, we used nasopharyngeal (NP) specimens that were obtained with calcium-alginate swabs, transported in Regan-Lowe transport medium, and in the laboratory placed on Regan-Lowe agar and modified Stainer Scholte broth.¹⁰ IgG and IgA antibodies to *B. pertussis* antigens were determined at Lederle laboratories and agglutination assays were performed in our central study laboratory in Erlangen, Germany. During the final year of follow-up, PCR for detection of *B. pertussis* (but not *B. parapertussis*) was also used for diagnosis. These studies were performed in Basel, Switzerland and the methods have been previously described and preliminary findings reported.^{17,23} Briefly, specimens for PCR were collected using a second Dacron NP swab (MAST, Hamburg, Germany). Oligonucleotide primers (pTp1 and pTp2), which amplify a 191-bp-sized DNA fragment from the PT operon that is specific for *B. pertussis*, were used. The PCR-amplified products were visualized by dot blot analysis followed by hybridization with a digoxigenin labeled probe and rated as 1+, 2+, or 3+ in comparison with positive controls representing ~1 to 10, 11 to 50, and >50 *B. pertussis* organisms, respectively. In addition to a positive control, each assay run contained internal and external negative controls. One blinded external negative control specimen was included with each 10 samples sent to the PCR laboratory. In addition to PCR samples from this vaccine efficacy trial, PCR samples from another study as well as routine diagnostic samples were sent in the same shipments to the PCR laboratory. All laboratory personnel were unaware of any clinical information on the respective patients.

Study subjects were monitored for adverse events and cough illnesses by biweekly phone calls. If a cough illness was noted, then the study physician was to obtain a culture and acute blood for serology. If the cough illness persisted for >2 weeks the subject or family member was seen by a Central Investigator who performed a standardized evaluation and made a clinical diagnosis. Furthermore, a convalescent serum specimen was to be obtained 4 to 6 weeks after onset of illness.

All statistical analyses were performed by use of the Superior Performing Software System (SPSS Inc, Chicago, IL). For comparisons of mean values *t* tests for independent samples were applied and differences among proportions were determined by the χ^2 test or Fisher's exact test.

RESULTS

Three hundred ninety-two subjects with cough illnesses or exposure to a family member with suspected pertussis had NP specimens collected for PCR assay. Of these 392 subjects, 376 had a NP specimen collected for culture. Because of parental refusal or technical difficulties in getting a venous blood sample, 1 or more serum specimens for antibody studies were available in only 282 instances (72%). Twenty study subjects had contact with a family member with culture confirmed *B. pertussis* infection. Overall, 273 (70%) subjects had NP specimens for PCR and culture and serologic evaluation.

The PCR results and the immunization status of trial participants are demonstrated in Table 1. In 86

TABLE 1. Immunization Status and PCR Results in 392 Trial Participants

Vaccine	PCR Result					
	Negative No. (%)	Any Positive No. (%)	1+ Positive No. (%)	2+ Positive No. (%)	3+ Positive No. (%)	Total No. (%)
DT	52 (58)	38 (42)*†‡	5 (6)	9 (10)	24 (26)	90 (23)
DTaP	123 (80)	30 (20)†‡	6 (4)	10 (7)	14 (9)	153 (39)
DTP	131 (88)	18 (12)*†	3 (2)	13 (9)	2 (1)	149 (38)
Total	306 (78)	86 (22)	14 (4)	32 (8)	40 (10)	392 (100)

* $P < .0001$.† $P = .05$.‡ $P = .0001$.

subjects, the PCR result was positive for *B pertussis* with the highest rate (42%) among DT recipients. When the grading of PCR positivity was analyzed, NP specimens from DT recipients more frequently were strongly positive (3+) compared with those from DTaP and DTP recipients (24/38 = 63% vs 14/30 = 47% and 2/18 = 11%, respectively).

In 376 subjects, NP specimens for both culture and PCR were available (Table 2). In all 23 subjects with cultures positive for *B pertussis*, the PCR assay was also positive and 21 of them (91%) were rated 3+. All 8 subjects with NP specimens that were culture-positive for *B parapertussis* had negative PCR studies. In addition, 59 of the 345 subjects with culture-negative NP specimens had positive PCR findings resulting in a 3.6-fold higher yield of positive PCRs compared with positive cultures. Of 39 specimens rated 3+ by PCR, 21 (54%) were confirmed by a positive culture. In contrast, of 31 specimens rated 2+ by PCR and 12 specimens rated 1+ by PCR only 3% and 8%, respectively, were also positive for *B pertussis* by culture. The mean ages of children with positive culture; negative culture/positive PCR; and negative culture/negative PCR were identical ($2.4 \pm .4$ years, $2.4 \pm .5$ years, and $2.3 \pm .6$ years, respectively). The duration of illness at the time of specimen sampling was also compared among the 3 subgroups. Timing of NP sample did not seem to influence the outcome of culture and PCR tests in the subjects studied in this trial: of 200 children with ≤ 14 days of illness when the NP specimen was taken, 6% were culture-positive for *B pertussis* and an additional 16% were positive by PCR. The respective figures in 178 children with > 14 days of illness when the NP specimen was taken were 6% and 14% ($P = .58$). The mean duration of illness at the time the NP specimen was taken was 13.6 ± 9 days (median: 12 days) in children with positive cultures for *B pertussis* compared with 16.7 ± 16 days (median: 12 days) and 17.0 ± 14 days (median: 14 days) in those with neg-

ative culture/positive PCR and negative culture/negative PCR, respectively (all P values $> .2$).

A comparison of the PCR findings and other confirmative diagnostic criteria is demonstrated in Table 3. Culture (available in 376 subjects), serology ($n = 282$), and information on household contact with a laboratory confirmed case of *B pertussis* infection ($n = 380$) were used for this analysis. Using a positive serology specific for *B pertussis* as the standard, overall sensitivity of PCR was 61% and specificity was 88%. Of the 26 subjects with a positive PCR but negative serology, 17 had acute serum specimens only (1 with a significantly elevated IgA antibody value against pertactin) and 9 had both acute and convalescent serum specimens (1 with significant IgG antibody rises against FHA and pertactin).

When a positive serology and/or a positive culture and/or a household contact to a case with culture-confirmed *B pertussis* infection were used as the standard, sensitivity, and specificity rates were very similar (60% and 90%, respectively). When only 3+ positive PCR assays were considered positive, sensitivity decreased to 42% (24/57), and specificity increased to 97% (219/225) with serology as the standard. Using the combined criteria as the standard, sensitivity of a 3+ positive PCR was 41% (29/71) and specificity is 98% (204/208).

Of the 392 subjects evaluated, 14 did not have a cough illness but were exposed to a household member with a cough illness. Of these 14 children, 2 were positive by PCR but not by culture. The clinical symptoms of the 378 subjects with cough illnesses and PCR assays are presented in Table 4. As can be seen, the duration of cough illness, the presence of symptoms characteristic of pertussis (ie, paroxysmal cough, whooping, and/or posttussive vomiting) and a clinical diagnosis of probable or definite pertussis were all significantly less pronounced in children with negative PCR results compared with those with a positive PCR result. The comparative findings in

TABLE 2. Comparison of Culture and PCR for the Diagnosis of *Bordetella* Infections in 376 Subjects in Whom NP Specimens for Both Assays Were Available

PCR Result	Culture Result			Total No. (%)
	Negative No. (%)	<i>B pertussis</i> No. (%)	<i>B parapertussis</i> No. (%)	
Negative	286 (97)	0 (0)	8 (3)	294 (78)
Positive (1+)	11 (92)	1 (8)	0 (0)	12 (3)
Positive (2+)	30 (97)	1 (3)	0 (0)	31 (8)
Positive (3+)	18 (46)	21 (54)	0 (0)	39 (10)
Total	345 (92)	23 (6)	8 (2)	376 (100)

TABLE 3. Serology and Combined Diagnostic Confirmative Criteria Indicative of *B pertussis* Infection in Comparison With PCR Results in Study Subjects

PCR Result	Confirmative Criteria			
	Serology Positive for <i>B pertussis</i> Infection No. (%)	Serology Negative for <i>B pertussis</i> Infection No. (%)	Any Confirmative Criterion Positive for <i>B pertussis</i> Infection* No. (%)	All Confirmative Criteria Negative for <i>B pertussis</i> Infection† No. (%)
Positive	35 (61)	26 (12)	43 (60)	21 (10)
3+ positive	24 (42)	6 (3)	29 (41)	4 (2)
Negative	22 (39)	199 (88)	28 (40)	187 (90)
Total	57 (100)	225 (100)	71 (100)	208 (100)

* Serology and/or culture and/or household contact positive.

† Serology and culture and household contact negative.

TABLE 4. Clinical Characteristics in 378 Subjects With Cough Illnesses in Relation to PCR Results

PCR Result	Clinical Characteristics		
	Duration of Cough (Mean ± Standard Deviation in Days)	Presence of PWV‡ <i>n</i> Positive (% Positive)	Clinical Diagnosis of Pertussis† <i>n</i> Positive (% Positive)
Negative (<i>n</i> = 294)	36 ± 22*	187 (64)**	28 (10)***
Positive (any) (<i>n</i> = 84)	45 ± 26	65 (77)	37 (44)
Positive (1+) (<i>n</i> = 14)	42 ± 19	10 (71)	4 (29)
Positive (2+) (<i>n</i> = 30)	43 ± 23	17 (57)	7 (23)
Positive (3+) (<i>n</i> = 40)	48 ± 30	38 (95)	26 (65)
Total (<i>n</i> = 378)	38 ± 23	252 (67)	65 (17)

* $P < .01$; ** $P = .02$; *** $P < .001$ (for negative vs any positive).

† Probable or definite.

‡ Presence of paroxysmal cough or whooping or posttussive vomiting.

the 3 subgroups of PCR positives indicate more serious illness in those with 3+ positivity compared with those with 1+ or 2+ positivity of PCR. Illness in patients with a 3+ positive PCR was very similar to those in 23 culture-positive patients of whom 100% experienced paroxysmal cough, whooping, and/or posttussive vomiting; 78% had a clinical diagnosis of definite or probable pertussis; and the mean duration of cough was 54 ± 34 days.

Finally, we also looked at symptoms of pertussis in the 84 subjects with cough illnesses and a positive PCR for *B pertussis* by vaccine group (Table 5). Although the mean duration of cough was longest in vaccine failure cases among DTP recipients (60 days vs 32 days and 48 days in DTaP and DT vaccinees, respectively), the frequency of paroxysmal cough or whooping or posttussive vomiting among them was lowest (50% vs 76% and 92%). This was associated with a low rate of clinical diagnosis of pertussis

(22%) compared with the rate in DTaP (34%) and DT (62%) recipients.

During the year in which this present study was conducted, our laboratory also handled specimens for *B pertussis* PCR as part of another study and in routine diagnosis. A total of 332 blinded negative controls were sent along with these studies and patient samples and there were 4 (1.2%) false-positive results indicating laboratory error in a specific PCR run. All results from runs with a positive result in a negative control were discarded.

DISCUSSION

The laboratory diagnosis of a *B pertussis* infection in the clinical setting is not an easy task. Recovery of the organism from a NP specimen by culture has been the standard because of its high specificity. However, sensitivity is less than optimal.^{10,29} Adding specific serology (ELISA techniques) to the diagnos-

TABLE 5. Comparison of Clinical Characteristics in 84 Subjects With Cough Illnesses and Positive PCR for *B pertussis* by Type of Vaccine Received

Characteristic	Vaccine			<i>P</i> Values*		
	DT <i>n</i> = 37	DTaP <i>n</i> = 29	DTP <i>n</i> = 18	DT Versus DTaP	DT Versus DTP	DTaP Versus DTP
Duration of cough (mean ± standard deviation in d)	48 ± 18	32 ± 23	60 ± 35	.003		.006
Presence of PWV+ (% positive)	92	76	50	.07	.001	.07
Clinical diagnosis of probable or definite pertussis (% positive)	62	34	22	.02	.006	

* Only *P* values <.1 are shown.

† Paroxysmal cough or whooping or posttussive vomiting.

tic program greatly increases the sensitivity but questions concerning its specificity have been raised because PT is the only antigen specific for *B pertussis* among *Bordetella* spp (reviewed in reference 29). In addition, the ELISA serologic techniques used in vaccine trials and other research are labor intensive; they also require both acute-phase and convalescent-phase sera so that these results have little clinical usefulness. ELISA techniques adapted for clinical diagnosis that use single sera frequently have both low sensitivity and specificity. Therefore, a method such as PCR with greater sensitivity than culture would be a useful addition for diagnosis if its reliability was proven. However, soon after the development of several different methods for detection of *Bordetella* spp by PCR, concerns were raised about the specificity of a positive result when a concomitant culture was negative. A group of experts in the field proposed that "a PCR-positive result in someone with mild or no symptoms should be interpreted with caution and, if possible, other markers such as serology or epidemiology should be added."³⁰

Since that expert report, only a few studies have been published in which specificity of PCR for diagnosis of *B pertussis* infection was evaluated by serology.^{21,25,26,28}

Our findings presented here are unique in that the PCR results were reported not only qualitatively but also semiquantitatively with 3 grades of positivity. Characteristics of cough illnesses correlated directly with the PCR result in that the frequency of typical symptoms of pertussis increased with the grade of positivity. Furthermore, of unvaccinated children with a positive PCR the majority was 3+ positive, whereas among those who had been immunized against pertussis, 2+ and 1+ positive results predominated. This is in accordance with previously published reports that had shown that confirmed cases of *B pertussis* infection are less severe in vaccinated than in unvaccinated children.^{1-4,6-8} Therefore, it is tempting to speculate that vaccine-induced immunity prevents extensive multiplication of the bacteria on the mucosal surfaces after infection (reflected by a moderately or weakly positive PCR). In support of this hypothesis, it has recently been shown experimentally by a quantitative PCR method that the total number of detectable *B pertussis* genomes correlated well with the number of viable bacteria detected by culture.²⁷ Therefore, it is not surprising, that *B pertussis* could be isolated from culture in <10% of our NP specimens with 1+ or 2+ positive PCR results compared with an isolation rate of 54% in those specimens that were 3+ positive by PCR. Interestingly, duration of cough when the NP specimens were collected did not seem to influence the detection rate of *B pertussis* by culture or PCR in this study. This is in contrast to previous findings²⁹ for which we have no ready explanation.

In our analysis, sensitivity of PCR was 61% and specificity was 88% with serology as the standard. With an extended gold standard (including a positive serology and/or a positive culture and/or a household contact to a case with culture-confirmed *B pertussis* infection) the respective values were very

similar (60% and 90%). One could ask why PCR is not 100% specific. In this respect, it is interesting to note that specificity indeed is very close to 100% (97%–98%) when only 3+ PCR-positive specimens are considered true positives, whereas including all positive specimens irrespective of grading results in specificity of 90% or less. Does this mean that 1+ and 2+ positive specimens are false-positives? Given the fact that only 1 or a few of the bacteria in a specimen targeted by the specific primers can lead to a positive PCR result and contamination may easily occur inside and outside of the laboratory,³¹ this seems to be a possibility. However, based on the data we present, there is strong evidence that contamination was an unlikely cause of our findings and that PCR in our study was very specific. First, none of 8 samples positive for *B parapertussis* by culture were positive for *B pertussis* by PCR. Second, during the study period a total of 332 blinded negative controls were sent to the PCR laboratory along with study and clinical specimens on a routine basis and only 4 (1.2%) were PCR-positive indicating laboratory contamination. Third, severity of cough in patients with a positive PCR was clearly different from those with a negative PCR. And fourth, specimens that were 1+ and 2+ positive by PCR were more often found in pertussis vaccinees than in control patients.

Unfortunately, a comparison with the other 4 studies where serology was part of the diagnostic program is very difficult attributable to limited data reported and/or differences in the diagnostic criteria of a positive serology. In the study by Li et al,²¹ data on serology are only given in those individuals with negative culture results. Among those, of 15 individuals with a positive serology, only 1 was positive by PCR. Reizenstein et al²⁵ also report a comparison of PCR and serology findings only in those subjects in whom culture was negative for *B pertussis*. Under these circumstances, sensitivity of PCR was 56%, and thus, in the range of our findings. In contrast, van der Zee et al²⁶ found a low sensitivity of 21% for PCR in comparison with serology. In their study, high age of patients (50% were >5 years old) and specimen sampling late in the course of the illness (>3 weeks of cough in 65% of patients) were blamed for the apparent low sensitivity of PCR. Finally, a calculation based on the data reported by Lind-Brandberg et al²⁸ using a standard combining culture, serology, and exposure reveals a sensitivity of 65% for PCR, which is also in the range of our findings.

CONCLUSION

In summary, our analyses confirm the superior sensitivity of PCR compared with conventional culture. Clinical validation of graded PCR revealed that characteristics of cough in a patient with a 3+ PCR are very similar to those in a culture-positive patient, whereas most of the patients with 1+ or 2+ PCR experience less typical illness. If careful internal and external controls are applied, PCR is a useful tool in addition to culture and serology for diagnosis of *B pertussis* infection. However, specific serology remains necessary for the diagnosis of *Bordetella* spp infection in research situations.

ACKNOWLEDGMENT

This study was sponsored by Wyeth-Lederle Pediatrics and Vaccines, Pearl River, New York.

REFERENCES

1. Trollfors B, Taranger J, Lagergård T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. *N Engl J Med*. 1995;333:1045–1050
2. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. *N Engl J Med*. 1996;334:341–348
3. Gustafsson L, Hallander H, Olin P, et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. *N Engl J Med*. 1996;334:349–355
4. Trollfors B, Taranger J, Lagergard T, et al. Efficacy of a monocomponent pertussis toxoid vaccine after household exposure to pertussis. *J Pediatr*. 1997;130:532–536
5. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to *Bordetella pertussis*. *Vaccine*. 1998;15:1907–1916
6. Stehr K, Cherry JD, Heininger U, et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. *Pediatrics*. 1998;101:1–11
7. Cherry JD, Heininger U, Stehr K, Christenson P. The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. *Pediatrics*. 1998;102:909–912
8. Heininger U, Cherry JD, Stehr K, et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German infants following household exposure. *Pediatrics*. 1998;102:546–553
9. Heininger U, Stehr K, Christenson P, Cherry JD. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against *Bordetella parapertussis* infection. *Clin Infect Dis*. 1999;28:602–604
10. Heininger U, Cherry JD, Eckhardt T, Lorenz C, Christenson P, Stehr K. Clinical and laboratory diagnosis of pertussis in the regions of a large vaccine efficacy trial in Germany. *Pediatr Infect Dis J*. 1993;12:504–509
11. Heininger U, Klich K, Stehr K, Cherry JD. Clinical findings in *Bordetella pertussis* infections: results of a prospective multicenter surveillance study. *Pediatrics*. 1997;100(6). URL: <http://www.pediatrics.org/cgi/content/full/100/6/e10>
12. Houard S, Hackel C, Herzog A, Bollen A. Specific identification of *Bordetella pertussis* by the polymerase chain reaction. *Res Microbiol*. 1989;140:477–484
13. Glare EM, Paton JC, Premier RR, Lawrence AJ, Nisbet IT. Analysis of a repetitive DNA sequence from *Bordetella pertussis* and its application to the diagnosis of pertussis using the polymerase chain reaction. *J Clin Microbiol*. 1990;28:1982–1987
14. Olcen P, Backman A, Johansson B, et al. Amplification of DNA by the polymerase chain reaction for the efficient diagnosis of pertussis. *Scand J Infect Dis*. 1992;24:339–345
15. Douglas E, Coote JG, Parton R, McPheat W. Identification of *Bordetella pertussis* in nasopharyngeal swabs by PCR amplification of a region of the adenylate cyclase gene. *J Med Microbiol*. 1993;38:140–144
16. Reizenstein E, Johanson B, Mardin L, Abens J, Möllby R, Hallander HO. Diagnostic evaluation of polymerase chain reaction discriminative for *Bordetella pertussis*, *B. parapertussis*, and *B. bronchiseptica*. *Diagn Microbiol Infect Dis*. 1993;17:185–191
17. Schläpfer G, Senn HP, Berger R, Just M. Use of the polymerase chain reaction to detect *Bordetella pertussis* in patients with mild or atypical symptoms of infection. *Eur J Clin Microbiol Infect Dis*. 1993;12:459–463
18. van der Zee A, Agterberg C, Peeters M, Schellekens J, Mooi FR. Polymerase chain reaction assay for pertussis: simultaneous detection and discrimination of *Bordetella pertussis* and *Bordetella parapertussis*. *J Clin Microbiol*. 1993;31:2134–2140
19. Grimpel E, Begue P, Anjak I, Betsou F, Guiso N. Comparison of polymerase chain reaction, culture and western immunoblot serology for diagnosis of *Bordetella pertussis* infection. *J Clin Microbiol*. 1993;31:2745–2750
20. He Q, Mertsola J, Soini H, Viljanen MK. Sensitive and specific polymerase chain reaction assays for detection of *Bordetella pertussis* in nasopharyngeal specimens. *J Pediatr*. 1994;124:421–426
21. Li ZM, Jansen DL, Finn TM, et al. Identification of *Bordetella pertussis* infection by shared-primer PCR. *J Clin Microbiol*. 1994;32:783–789
22. Lichtinghagen R, Diedrich-Glaubitz R, von Hörsten B. Identification of *B. pertussis* in nasopharyngeal swabs using the polymerase chain reaction: evaluation of detection methods. *Eur J Clin Chem Clin Biochem*. 1994;32:161–167
23. Schläpfer G, Cherry JD, Heininger U, et al. Polymerase chain reaction identification of *Bordetella pertussis* infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. *Pediatr Infect Dis J*. 1995;14:209–214
24. Mastrantonio P, Stefanelli P, Giuliano M. Polymerase chain reaction for the detection of *Bordetella pertussis* in clinical nasopharyngeal aspirates. *J Med Microbiol*. 1996;44:261–266
25. Reizenstein E, Lindberg L, Möllby R, Hallander HO. Validation of nested *Bordetella* PCR in a pertussis vaccine trial. *J Clin Microbiol*. 1996;34:810–815
26. van der Zee A, Agterberg C, Peeters M, Mooi F, Schellekens J. A clinical validation of *Bordetella pertussis* and *Bordetella parapertussis* polymerase chain reaction: comparison with culture and serology using samples from patients with suspected whooping cough from a highly immunized population. *J Infect Dis*. 1996;174:89–96
27. Erlandsson A, Backman A, Nygren M, Lundeberg J, Olcen P. Quantification of *Bordetella pertussis* in clinical samples by colorimetric detection of competitive PCR products. *APMIS*. 1998;106:1041–1048
28. Lind-Brandberg L, Welinder-Olsson C, Lagergard T, Taranger J, Trollfors B, Zackrisson G. Evaluation of PCR for diagnosis of *Bordetella pertussis* and *Bordetella parapertussis* infections. *J Clin Microbiol*. 1998;36:679–683
29. Müller FM, Hoppe JE, Wirsing von König CH. Laboratory diagnosis of pertussis: state of the art in 1997. *J Clin Microbiol*. 1997;35:2435–2443
30. Meade BD, Bollen A. Recommendations for use of the polymerase chain reaction in the diagnosis of *Bordetella pertussis* infections. *J Med Microbiol*. 1994;41:51–55
31. Taranger J, Trollfors B, Lind L, Zackrisson G, Beling-Holmquist K. Environmental contamination leading to false-positive polymerase chain reaction for pertussis. *Pediatr Infect Dis J*. 1994;13:936–937. Letter

Clinical Validation of a Polymerase Chain Reaction Assay for the Diagnosis of Pertussis by Comparison With Serology, Culture, and Symptoms During a Large Pertussis Vaccine Efficacy Trial

Ulrich Heininger, Gabriela Schmidt-Schlöpfer, James D. Cherry and Klemens Stehr

Pediatrics 2000;105:e31

DOI: 10.1542/peds.105.3.e31

Updated Information & Services	including high resolution figures, can be found at: http://pediatrics.aappublications.org/content/105/3/e31
References	This article cites 30 articles, 10 of which you can access for free at: http://pediatrics.aappublications.org/content/105/3/e31#BIBL
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): Infectious Disease http://www.aappublications.org/cgi/collection/infectious_diseases_sub
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.aappublications.org/site/misc/Permissions.xhtml
Reprints	Information about ordering reprints can be found online: http://www.aappublications.org/site/misc/reprints.xhtml

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Clinical Validation of a Polymerase Chain Reaction Assay for the Diagnosis of Pertussis by Comparison With Serology, Culture, and Symptoms During a Large Pertussis Vaccine Efficacy Trial

Ulrich Heininger, Gabriela Schmidt-Schläpfer, James D. Cherry and Klemens Stehr

Pediatrics 2000;105:e31

DOI: 10.1542/peds.105.3.e31

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://pediatrics.aappublications.org/content/105/3/e31>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2000 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 1073-0397.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

